Policy changes Backwork has recorded, newest first. The most recent change on record is from October 24, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
86,510 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| May 18, 2026 | Capital Blue Cross | Genetic Testing for Facioscpulohumeral Muscular Dystrophy | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Genetic Testing for FLT3, NPM1 and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Genetic Testing for CHARGE Syndrome | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Genetic Testing for Alzheimer Disease (Formerly Diagnostic Testing and Risk Assessment for Alzheimer Disease) | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Genetic Testing for Alpha Thalassemia | Criteria changed |
| May 18, 2026 | Capital Blue Cross | General Approach to Genetic Testing | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Gene Expression Profiling for Uveal Melanoma | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Gastric Electrical Stimulation | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Ganglion Impar Block | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Facet Joint Injections and Medal Branch Blocks | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Extracorporeal Photopheresis | Criteria changed |
| May 18, 2026 | Capital Blue Cross | External Infusion Pumps for Insulin Delivery and Automated Insulin Delivery Systems | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Evaluation of Biomarkers for Alzheimer's Disease | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Electromyography (EMG) (Needle and Non-Needle) of the Anal or Urethral Sphincter | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion Procedures | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Electrical Bone Growth Stimulation of the Appendicular Skeleton | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Durable Medical Equipment and Supplies (DME) | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Donor Lymphocyte Infusion for Hematologic Malignancies Treated with an Allogeneic HCT | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Cosmetic and Reconstructive Surgery | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Keratoprosthesis and Corneal Surgery (Formerly Corneal Surgery) | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Continuous Glucose Monitoring | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Computer-Assisted Corneal Topography | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Cochlear Implant | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Chromosomal Microarray Testing for the Evaluation of Pregnancy Loss | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Carrier Screening for Genetic Diseases | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Bioimpedance Devices for Detection and Management of Lymphedema | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Baroreflex Stimulation Device | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Allergy Testing and Immunotherapy | Criteria changed |
| May 18, 2026 | Capital Blue Cross | Actigraphy | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Zanidatamab-hrii (Ziihera) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Ziv-Aflibercept (Zaltrap) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Zolbetuximab-clzb (Vyloy) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Viltolarsen (Viltepso) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Verteporfin (Visudyne) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Triamcinolone Acetonide Injectable Suspension (Xipere) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Transcranial Magnetic Stimulation (TMS) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Tisotumab Vedotin-tftv (Tivdak) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Thyrotropin Alfa (Thyrogen) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Teplizumab-mzwv (Tzield) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Teprotumumab-trbw (Tepezza) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Temsirolimus (Torisel) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Temozolomide (Temodar) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Teclistamab-cqyv (Tecvayli) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Ustekinumab Products: Ustekinumab (Stelara); Ustekinumab-auub (Wezlana); Ustekinumab-srlf (Imuldosa); Ustekinumab-aauz (Otulfi); Ustenkinumab-ttwe (Pyzchiva), Ustekinumab-aekn (Selarsdi); Ustenkinumab-stba (Steqeyma); Ustenkinumba-kfce (Yesintek); ustekinumab; ustekinumab-aauz, ustekinumab-stba, ustekinumab-aekn ; ustenkinumab-ttwe; Ustekinumab-hmny (Starjemza) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Sotatercept-csrk (Winrevair) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Siltuximab (Sylvant) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Sacituzumab Govitecan-hziy (Trodelvy) | Criteria changed |
| May 18, 2026 | BlueCross BlueShield of Tennessee | Rozanolixizumab‐noli (Rystiggo) | Criteria changed |